Drug Treatment Study for Children with Hemophilia A

Clinical Trial Title

Safety and efficacy of turoctocog alfa pegol (N8-GP) in previously untreated patients with hemophilia A.

Clinical Trial Protocol Description:

Phase 3a open-label trial investigating the safety and efficacy of N8-GP (a recombinant, extended half-life factor VIII concentrate) for prophylaxis and treatment of bleeding episodes.

Clinical Trial Eligibility Criteria:

In order to participate you must meet the following criteria:

  • Have hemophilia A.
  • Are a male.
  • Are 6 years of age or younger.
  • Have never received any factor medications or blood products.

This is a partial list of elgibility requirements.

Study Details

Clinical Trial Investigator

Mindy Simpson, MD

Contact Information

Mindy Simpson, MD

(312) 942-3034